May 2, 2007 |
Genentech Inc. and Biogen Idec Inc. said their Rituxan cancer drug proved highly effective against multiple sclerosis in a small mid-stage trial, signaling a potential new way of treating the progressive neurological disease. The biotechnology companies said the Phase II trial involved 104 patients with the most common "relapsing-remitting" form of multiple sclerosis -- in which patients have varying levels of recovery and periods of remission between flare-ups of the autoimmune disease.
September 17, 2012 |
WOODLAND, Calif. - The worst U.S. drought in half a century is withering the nation's corn crop, but it's a fertile opportunity for makers of genetically modified crops. Agricultural biotechnology companies have been pouring hundreds of millions of dollars into developing plants that can withstand the effects of a prolonged dry spell. Monsanto Co., based in St. Louis, has received regulatory approval for DroughtGard, a corn variety that contains the first genetically modified trait for drought resistance.
October 4, 2002 |
The government has created a genetically engineered anthrax vaccine that promises to cut in half the six shots now needed for protection, and chosen two biotechnology companies to begin testing it. The $22.5-million contract award will allow California-based VaxGen Inc. and Britain's Avecia to test the experimental vaccine on people to see if it is safe and, if so, to see if it provides protection against the deadly bacteria.
August 29, 2006 |
Biotechnology companies Genentech Inc. and Biogen Idec Inc. said their cancer drug Rituxan showed hints of effectiveness against multiple sclerosis in a small mid-stage trial. The study involved 104 adults with the most common form of multiple sclerosis. It showed a statistically significant reduction among those given Rituxan in the total number of brain lesions, South San Francisco-based Genentech said. Rituxan is one of the biggest-selling treatments for non-Hodgkin's lymphoma.
June 14, 1985
The Rockville, Md., biotechnology firm said its contract to produce ingredients for Searle's popular sweetener, aspartame, will not be renewed when it expires Oct. 31. Genex has often been listed as one of the nation's five most promising biotechnology companies. Its sales to Searle in 1984 accounted for $20.2 million of Genex's product sales of $20.6 million and 58% of the company's total revenue of $34.8 million. Both companies declined to comment on why the contract will not be extended.